Economic drivers and trade-offs in antibody purification processes

Increasing titers in mammalian cell culture has recently shifted the focus of process development efforts towards improving the economics of product recovery and purification processes. Some argue that a paradigm shift may be required to ensure timely and cost-effective delivery of future antibody candidates. This paper discusses the key process economic drivers and the impact of scale and titer on downstream processing (DSP) economic trade-offs.